公开(公告)号：US20250129162A1

公开(公告)日：2025-04-24

申请号：US18901189

申请日：2024-09-30

Applicant: Genentech, Inc.

Inventor： Bernard Martin FINE ,  Teemu Tapani JUNTTILA ,  Mengsong LI ,  Teiko SUMIYOSHI ,  James Niall COOPER

IPC: C07K16/28 ,  A61K31/138 ,  A61K31/167 ,  A61K31/454 ,  A61K31/573 ,  A61K45/06

Abstract: The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.

公开(公告)号：US20240360229A1

公开(公告)日：2024-10-31

申请号：US18416525

申请日：2024-01-18

Applicant: Genentech, Inc.

Inventor： Christoph SPIESS ,  Baomei WANG ,  Ambrose Jon WILLIAMS ,  Cecilia Pui Chi CHIU ,  Michael Andrew DILLON ,  Teemu Tapani JUNTTILA ,  James Thomas KOERBER

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73

Abstract: The present invention provides anti-C-C motif chemokine receptor 8 (CCR8) antigen-binding molecules (e.g., bispecific antigen-binding molecules) and compositions thereof. The invention also features polynucleotides, vectors, host cells, methods of production, pharmaceutical compositions, methods of treating a disease or disorder, such as cancer, methods of depleting regulatory T cells, related uses and compositions for use, and kits for use with the one or more methods.